SXTP Key Statistics, Chart & Performance
The current stock price of SXTP is 1.01 USD. In the past month the price decreased by -31.29%. In the past year, price decreased by -77.56%.
SXTP Latest News, Press Relases and Analysis
SXTP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.19 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 19.64 | 491.06B | ||
| MRK | MERCK & CO. INC. | 11.1 | 244.18B | ||
| PFE | PFIZER INC | 7.82 | 142.37B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.05 | 94.14B | ||
| ZTS | ZOETIS INC | 19.25 | 54.09B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.47 | 22.70B | ||
| VTRS | VIATRIS INC | 4.49 | 12.20B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.18 | 11.05B | ||
| CORT | CORCEPT THERAPEUTICS INC | 87.83 | 8.14B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.46B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.04B |
Related stock screener links
About SXTP
Company Profile
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Company Info
60 DEGREES PHARMA INC
1025 Connecticut Avenue Nw, Suite 1000
WASHINGTON WASHINGTON DC US
Employees: 3
Phone: 12023275422
60 DEGREES PHARMA INC / SXTP FAQ
What does SXTP do?
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Can you provide the latest stock price for 60 DEGREES PHARMA INC?
The current stock price of SXTP is 1.01 USD.
Does SXTP stock pay dividends?
SXTP does not pay a dividend.
What is the ChartMill rating of 60 DEGREES PHARMA INC stock?
SXTP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting SXTP stock to perform?
8 analysts have analysed SXTP and the average price target is 7.14 USD. This implies a price increase of 606.93% is expected in the next year compared to the current price of 1.01.
What is the Price/Earnings (PE) ratio of 60 DEGREES PHARMA INC (SXTP)?
60 DEGREES PHARMA INC (SXTP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-21.66).
SXTP Technical Analysis
SXTP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SXTP. SXTP has a bad profitability rating. Also its financial health evaluation is rather negative.
SXTP Financial Highlights
Over the last trailing twelve months SXTP reported a non-GAAP Earnings per Share(EPS) of -21.66. The EPS decreased by -512.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -198.65% | ||
| ROE | -342.13% | ||
| Debt/Equity | 0.06 |
SXTP Forecast & Estimates
8 analysts have analysed SXTP and the average price target is 7.14 USD. This implies a price increase of 606.93% is expected in the next year compared to the current price of 1.01.
For the next year, analysts expect an EPS growth of 94.26% and a revenue growth 94.66% for SXTP